AG-490 (Tyrphostin B42): Potent JAK2/EGFR Inhibitor for Signal Transduction Research

Executive Summary: AG-490 (Tyrphostin B42) is a small-molecule tyrosine kinase inhibitor that selectively targets JAK2, EGFR, and ErbB2, with IC₅₀ values of 10 μM, 0.1 μM, and 13.5 μM, respectively (APExBIO). It is widely used to interrogate JAK-STAT and MAPK signaling pathways in cancer and immunological research (Zhang et al., 2025). AG-490 effectively blocks STAT3 activation and suppresses cytokine-induced JAK2 activity in various immune cell types. The compound is insoluble in water but dissolves in DMSO and ethanol under standardized conditions. AG-490 is provided by APExBIO with rigorous quality controls for research use only.

Biological Rationale

Signal transduction via the JAK-STAT and MAPK pathways is fundamental to cellular proliferation, differentiation, and immune responses (Zhang et al., 2025). JAK2 is a cytoplasmic tyrosine kinase that transduces cytokine signals, notably in hematopoietic and immune cells. Overactivation of JAK2 or STAT3 has been implicated in oncogenesis and immunopathological states, such as acute lymphoblastic leukemia (ALL) and mycosis fungoides. EGFR and ErbB2 are critical in growth factor signaling, with dysregulation frequently observed in solid tumors. Inhibition of these kinases allows researchers to model and dissect the roles of tyrosine kinase signaling in disease progression, immune modulation, and therapeutic resistance. Recent studies show that exosomal SNORD52 can induce M2 macrophage polarization through JAK2/STAT6 activation, highlighting the relevance of JAK2 inhibition in tumor microenvironment research (Zhang et al., 2025).

Mechanism of Action of AG-490 (JAK2/EGFR inhibitor)

AG-490 acts as an ATP-competitive inhibitor of tyrosine kinases, particularly JAK2, EGFR, and ErbB2. The compound inhibits JAK2 autophosphorylation, thereby preventing downstream STAT activation. In B cell precursors from ALL patients, AG-490 inhibits hyperactive JAK2 signaling. In eosinophils, it suppresses cytokine-induced JAK2 phosphorylation, leading to reduced STAT5 and MAPK pathway activity. In IL-2-dependent T cell lines, AG-490 blocks IL-2-induced proliferation (IC₅₀ = 25 μM) without altering IL-2 receptor chain expression. The inhibitor also prevents phosphorylation of STAT5a and STAT5b (IC₅₀ = 50–70 μM), and significantly reduces DNA binding activities of STAT5a/5b, STAT1, and STAT3 by 78%, 65%, and 65%, respectively (APExBIO). AG-490 demonstrates selectivity by targeting JAK2 and JAK3, with minimal off-target effects at defined concentrations. The blockade of JAK2/STAT signaling by AG-490 is instrumental in suppressing immunopathological responses and tumor-promoting phenotypes (Zhang et al., 2025).

Evidence & Benchmarks

• AG-490 inhibits JAK2 autophosphorylation with an IC₅₀ of approximately 10 μM in cell-based assays (APExBIO).
• EGFR inhibition by AG-490 is potent, with an IC₅₀ of 0.1 μM, supporting its utility in solid tumor signaling studies (APExBIO).
• The compound blocks STAT3 activation in mycosis fungoides-derived T cells, a model for cutaneous T-cell lymphoma (APExBIO).
• In IL-2-dependent T cell lines, AG-490 suppresses IL-2-induced proliferation (IC₅₀ = 25 μM) without affecting IL-2 receptor chain expression (APExBIO).
• AG-490 reduces IL-2-induced DNA binding activities of STAT5a/5b, STAT1, and STAT3 by 78%, 65%, and 65%, respectively (APExBIO).
• Recent work demonstrates that JAK2/STAT6 activation is essential for M2 macrophage polarization, and pharmacological inhibition of JAK2 can disrupt this process (Zhang et al., 2025).

This article extends prior reviews such as AG-490 (Tyrphostin B42): JAK2/EGFR Inhibitor for Signal T... by providing updated benchmarks on cytokine-induced signaling and integrating new findings on exosome-mediated macrophage polarization. For a mechanistic deep dive, see the contrast in Strategic Disruption of JAK2/STAT Signaling: AG-490 (Tyrp... , which presents an overview of translational strategies; this article focuses on experimentally validated parameters and limitations.

Applications, Limits & Misconceptions

AG-490 is a research-only reagent, widely leveraged in cancer biology, immunology, and signal transduction studies to:

• Dissect JAK/STAT and MAPK pathway functions in cell-based and animal models.
• Model immunopathological state suppression and cytokine signal modulation.
• Investigate the role of tyrosine kinase signaling in tumor microenvironment interactions, including macrophage polarization (Zhang et al., 2025).
• Benchmark pharmacological inhibition in acute lymphoblastic leukemia and mycosis fungoides research.

Common Pitfalls or Misconceptions

• AG-490 is not water-soluble; improper solvent use leads to precipitation and unreliable results.
• It is not suitable for therapeutic use in humans; intended for research applications only (APExBIO).
• High concentrations (>70 μM) may induce off-target effects or cytotoxicity not related to JAK/STAT inhibition.
• AG-490 does not inhibit all tyrosine kinases; it is selective for JAK2, EGFR, ErbB2, and, to a lesser extent, JAK3.
• Long-term storage of AG-490 solutions is discouraged due to instability; fresh preparation ensures reproducibility.

Workflow Integration & Parameters

Researchers should dissolve AG-490 at ≥14.7 mg/mL in DMSO or ≥4.73 mg/mL in ethanol using gentle warming and ultrasonic treatment. The solid compound should be stored at -20°C in desiccated conditions. Solutions must be freshly prepared and used immediately to ensure potency. Recommended working concentrations range from 0.1 μM (EGFR inhibition) to 70 μM (STAT5 phosphorylation inhibition). Always include appropriate vehicle controls and titrate concentrations for specific cell types and readouts. The AG-490 (JAK2/EGFR inhibitor) A4139 kit from APExBIO provides a validated, research-grade formulation. For integrated study designs, see Decoding the Frontiers of JAK-STAT Modulation: AG-490 (Ty..., which outlines workflow integration in multi-pathway interrogation; this article provides updated solvent compatibility and stability guidance.

Conclusion & Outlook

AG-490 (Tyrphostin B42) remains a pivotal tool for dissecting JAK2/EGFR signaling in cancer and immunopathology research. Its precise inhibition spectrum, validated IC₅₀ values, and robust experimental benchmarks support its use in advanced signal transduction modeling. Ongoing studies, such as those on exosome-driven macrophage polarization, further expand the utility of AG-490 in understanding tumor-immune interactions (Zhang et al., 2025). As a research reagent from APExBIO, AG-490 enables reproducible, high-impact investigation of tyrosine kinase signaling networks.